FCRLA/FCRLM1 Antibody [Alexa Fluor® 488]

• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 488

FCRLA/FCRLM1 Antibody [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant human FCRLA
  Pro270-Glu359
  Accession # Q7L513
• Specificity: Detects human FCRLA in direct ELISAs and Western blots. In direct ELISAs, approximately 5-10% cross-reactivity with recombinant mouse FCRLA is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

FCRLA (Fc Receptor-Like A; also known as FcRX, FcRL1 and Fc receptor Homolog Expressed in B cells/FREB) is a 40-44 kDa intracellular member of the Fc gamma RI class, FcR family, Immunoglobulin Superfamily of molecules. Initially, it is associated with germinal center B cells that are undergoing somatic hypermutation and class-switch recombination. Now, it is believed that all B cells (but not CD38⁺ plasma cells) are also FCRLA⁺. FCRLA is suggested to act as an ER chaperone during antibody maturation, and is known to bind to IgM, IgA, and IgG prior to their secretion. Human FCRLA is synthesized as a 359 amino acid (aa) precursor that contains a 27 aa signal sequence plus a mature region that contains two C2-type Ig-like domains (aa 70-159 and 170-257), and a C-terminal poly-Proline region (aa 269-315). Although there is no traditional ER retention signal, a viable substitute is assumed to exist in the N-terminus of the mature molecule. FCLRA is believed to exist naturally as a monomer; however, disulfide-linkage can occur during experimental manipulation. At least eight potential isoform variants have been reported. It is unclear if, or how frequently they are expressed. One utilizes an alternative start site 17 aa upstream of the standard site, a second contains a six aa insertion after Ala28, and a third possessess an four aa substitution for aa 29-166. Five show single block deletions; in random order, they involve aa 78-166, 27-166, 78-261, 21‑261 and 167-26. Over aa 270-359, human FCLRA shares 55% aa sequence identity with mouse FCRLA.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.